Wednesday, June 10, 2026
🇺🇸 FDA

P1 · Therapeutic area intelligence

Oncology patent intelligence

Anticancer agents, immuno-oncology, ADC, and oncology patent filings — grants, expirations, and assignee activity.

Patents
2,004

Quick answer

2,004 US pharmaceutical patents in our index match Oncology title keywords (A61K/A61P). Cross-link to related drug therapeutic-area hubs and company patent portfolios for full IP context.

  1. WO 2026114957

    DÉRIVÉS DE THIOPHÈNE 2-AMINO-3-CYANO SPIROCYCLIQUES ANNELÉS EN TANT QUE DÉGRADEURS DE KRAS POUR LE TRAITEMENT DU CANCER

    BOEHRINGER INGELHEIM INT GMBH [DE] · Granted Thu Jun 04 2026 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Wed May 30 2046 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. WO 2026114918

    DÉRIVÉS DE 2-AMINO-3-CYANO THIOPHÈNE ANNELÉS SPIROCYCLIQUES UTILISÉS EN TANT QU'INHIBITEURS DE KRAS POUR LE TRAITEMENT DU CANCER

    BOEHRINGER INGELHEIM INT GMBH [DE] · Granted Thu Jun 04 2026 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Wed May 30 2046 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 20260146049

    SPIROCYCLIC ANNULATED 2-AMINO-3-CYANO THIOPHENES AND DERIVATIVES FOR THE TREATMENT OF CANCER

    BOEHRINGER INGELHEIM INT [DE] · Granted Thu May 28 2026 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Wed May 23 2046 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. WO 2026109729

    COMBINAISON COMPRENANT LE CAPIVASERTIB ET L'ABIRATÉRONE POUR LE TRAITEMENT DU CANCER DE LA PROSTATE MÉTASTATIQUE SENSIBLE AUX HORMONES (MHSPC) DÉFICIENT EN PTEN

    ASTRAZENECA AB [SE] · Granted Thu May 28 2026 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Wed May 23 2046 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. WO 2026109631

    UTILISATION DE PROTÉINES ENGAGEANT LES LYMPHOCYTES T DANS LE TRAITEMENT DU CANCER

    BOEHRINGER INGELHEIM INT [DE] · Granted Thu May 28 2026 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Wed May 23 2046 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. WO 2026107136

    CONJUGUÉS ANTICORPS ANTI-CEACAM5-MÉDICAMENT POUR LE TRAITEMENT DU CANCER

    BRISTOL MYERS SQUIBB CO [US] · Granted Thu May 21 2026 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Wed May 16 2046 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. WO 2026100645

    MÉTHODES DE TRAITEMENT DES SYMPTÔMES VASOMOTEURS CHEZ DES PATIENTES ATTEINTES DE CANCER DU SEIN AVEC LE FÉZOLINÉTANT

    ASTELLAS PHARMA INC [JP] · Granted Fri May 15 2026 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Thu May 10 2046 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. WO 2026102199

    THÉRAPIE COMBINÉE D'UN INHIBITEUR DE PRMT5 ET DU DARAXONRASIB POUR UTILISATION DANS LE TRAITEMENT DU CANCER MTAP-NUL

    AMGEN INC [US] · Granted Fri May 15 2026 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Thu May 10 2046 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  9. WO 2026082715

    DÉPLÉTION DES MACROPHAGES ET VIRUS DE LA STOMATITE VÉSICULAIRE POUR LE TRAITEMENT DU CANCER

    BOEHRINGER INGELHEIM INT [DE] · Granted Thu Apr 23 2026 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Wed Apr 18 2046 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  10. WO 2026078619

    ASSOCIATION DE TALAZOPARIB ET D'ENZALUTAMIDE DANS LE TRAITEMENT DU CANCER DE LA PROSTATE MÉTASTATIQUE RÉSISTANT À LA CASTRATION

    PFIZER [US] · Granted Thu Apr 16 2026 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Wed Apr 11 2046 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  11. WO 2026078615

    ASSOCIATION DE TALAZOPARIB ET D'ENZALUTAMIDE DANS LE TRAITEMENT DU CANCER DE LA PROSTATE MÉTASTATIQUE RÉSISTANT À LA CASTRATION

    PFIZER [US] · Granted Thu Apr 16 2026 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Wed Apr 11 2046 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  12. WO 2026060304

    ADMINISTRATION SOUS-CUTANÉE D'UN AGENT ANTI-DLL3 POUR LE TRAITEMENT DU CANCER

    AMGEN INC [US] · Granted Thu Mar 19 2026 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Wed Mar 14 2046 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  13. WO 2026057739

    POLYTHÉRAPIE COMPRENANT DES ANTICORPS ANTI-CTLA4 ET DES ANTICORPS ANTI-PD-1 POUR LE TRAITEMENT DU CANCER DE L'OVAIRE RÉSISTANT AU PLATINE

    BIONTECH SE [DE] · Granted Thu Mar 19 2026 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Wed Mar 14 2046 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  14. WO 2026057740

    TRAITEMENT DU CANCER AVEC DES MOLÉCULES DE LIAISON THÉRAPEUTIQUES

    ASTRAZENECA AB [SE] · Granted Thu Mar 19 2026 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Wed Mar 14 2046 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  15. WO 2026042803

    UTILISATION D'UN ANTICORPS BISPÉCIFIQUE ANTI-CLDN4/ANTI-CD137 EN COMBINAISON AVEC UN MÉDICAMENT À BASE DE PLATINE POUR LE TRAITEMENT DU CANCER

    ASTELLAS PHARMA INC [JP] · Granted Thu Feb 26 2026 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Wed Feb 21 2046 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  16. WO 2026041780

    POLYTHÉRAPIE COMPRENANT DES ANTICORPS ANTI-CTLA4 ET UNE CHIMIOTHÉRAPIE POUR LE TRAITEMENT DU CANCER

    BIONTECH SE [DE] · Granted Thu Feb 26 2026 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Wed Feb 21 2046 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  17. WO 2026039321

    MÉTHODES DE TRAITEMENT DU CANCER DE LA PROSTATE

    AMGEN INC [US] · Granted Thu Feb 19 2026 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Wed Feb 14 2046 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  18. US 20260034134

    TREATMENT OF CANCER WITH METASTASES IN THE CENTRAL NERVOUS SYSTEM

    BOEHRINGER INGELHEIM INT [DE] · Granted Thu Feb 05 2026 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Wed Jan 31 2046 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  19. WO 2025261951

    POLYTHÉRAPIE AVEC UN ANTICORPS ANTI-CA19-9 ET DU FOLFIRINOX DANS LE TRAITEMENT DU CANCER

    BIONTECH SE [DE] · Granted Fri Dec 26 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Thu Dec 21 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  20. US 2025388678

    Methods, Combinations, and Uses for the Treatment of Muscle Invasive Bladder Cancer

    ASTRAZENECA AB [SE] · Granted Thu Dec 25 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Wed Dec 20 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  21. WO 2025250569

    TRAITEMENTS DU CANCER UTILISANT DES INHIBITEURS DE PRMT5 MTA-COOPÉRATIFS ET DES INHIBITEURS DE MAT2A

    AMGEN INC [US] · Granted Thu Dec 04 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Wed Nov 29 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  22. US 12427173

    Use of bacteria, bacterial products, and other immunoregulatory entities in combination with anti-CTLA-4 and/or anti-PD-1 antibodies to treat solid tumor malignancies

    Biomed Valley Discoveries, Inc. · Granted Tue Sep 30 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 25 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  23. US 12427151

    Compositions and method of treating cancer

    The Regents of the University of California · Granted Tue Sep 30 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 25 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  24. US 12427148

    Cancer treatment targeted to tumor adaptive responses to protein synthesis stress

    The Regents of the University of California · Granted Tue Sep 30 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 25 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  25. US 12420113

    Methods and apparatus for applying tumor treating fields combined with personalized ultra-fractionated stereotactic adaptive radiotherapy

    The Board of Regents of the University of Texas System · Granted Tue Sep 23 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 18 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  26. US 12421316

    Bispecific immunotoxins targeting human CD25+CCR4+ tumors and regulatory T-cells

    The Regents of the University of Colorado, a Body Corporate · Granted Tue Sep 23 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 18 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  27. US 12415843

    Antibody-interferon fusion proteins for enhancing adoptive T cell therapies for the treatment of cancer

    The Regents of the University of California · Granted Tue Sep 16 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 11 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  28. US 12414995

    Bifunctional compounds comprising Apcin-A and their use in the treatment of cancer

    Northwestern University · Granted Tue Sep 16 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 11 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  29. US 12414983

    CD200AR ligands for cancer immunotherapy

    Regents of the University of Minnesota · Granted Tue Sep 16 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 11 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  30. US 12415863

    Compositions and methods for treating cancer

    THE REGENTS OF THE UNIVERSITY OF MICHIGAN · Granted Tue Sep 16 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 11 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  31. US 12409224

    Compositions and methods for the treatment of VEN/AZA resistant acute myeloid leukemia

    The Regents of the University of Colorado, a Body Corporate · Granted Tue Sep 09 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 04 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  32. US 12403202

    Dosage of claudin-6 conjugates for cancer treatment

    The Regents of the University of California · Granted Tue Sep 02 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 28 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  33. US 12391741

    T cell receptors that bind to mixed lineage leukemia (MLL)-specific phosphopeptides and methods of use thereof

    MiNK Therapeutics, Inc. · Granted Tue Aug 19 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 14 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  34. US 12383534

    Methods for treating cancer

    Regents of the University of Minnesota · Granted Tue Aug 12 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 07 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  35. US 12383555

    Methods of treating cancers

    FOGHORN THERAPEUTICS INC. · Granted Tue Aug 12 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 07 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  36. US 12383629

    DNA-affibody-drug nanoparticles for inhibiting the metastasis of cancer cells overexpressing HER2

    ARIZONA BOARD OF REGENTS FOR AND ON BEHALF OF ARIZONA STATE UNIVERSITY · Granted Tue Aug 12 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 07 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  37. US 12383538

    Use of mTOR inhibitors for prevention of intestinal polyp growth and cancer

    The Board of Regents of the University of Texas System · Granted Tue Aug 12 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 07 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  38. US 12377115

    Combination immunotherapies for treatment of cancer

    PrimeVax Immuno-Oncology · Granted Tue Aug 05 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 31 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  39. US 12377106

    Piperidinylpyrazine-carboxamide compounds for treating and preventing cancer and for degrading BTK

    NURIX THERAPEUTICS, INC. · Granted Tue Aug 05 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 31 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  40. US 12378201

    Histone demethylase inhibitors for treating cancers

    The Board of Regents of the University of Texas System · Granted Tue Aug 05 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 31 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  41. US 12377068

    In vitro and xenograft anti-tumor activity of a halogenated-xanthene against refractory pediatric solid tumors

    Provectus Pharmatech, Inc. · Granted Tue Aug 05 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 31 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  42. US 12370256

    Activation of resident memory T cells for the treatment of cancer

    Regents of the University of Minnesota · Granted Tue Jul 29 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 24 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  43. US 12370229

    Methods of treating bladder cancer

    CG ONCOLOGY, INC. · Granted Tue Jul 29 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 24 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  44. US 12370175

    Glucocorticoid receptor modulators to treat pancreatic cancer

    Corcept Therapeutics Incorporated · Granted Tue Jul 29 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 24 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  45. US 12371434

    MLL1 inhibitors and anti-cancer agents

    CHINA NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH CO., LTD. · Granted Tue Jul 29 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 24 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  46. US 12371499

    Method of treating cancer using anti-AV8 antibodies

    The Regents of the University of California · Granted Tue Jul 29 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 24 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  47. US 12371500

    Il-7R-alpha specific antibodies for treating acute lymphoblastic leukemia

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Tue Jul 29 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 24 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  48. US 12365659

    Non-polyamine based polyamine transport inhibitors and their use in the treatment of human cancers

    SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE · Granted Tue Jul 22 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 17 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

How many Oncology patents are indexed?

2,004 patents match our Oncology classifier (title keywords in USPTO records).

Is this legal or medical advice?

No — patent intelligence is for professional reference. Verify expiration and FTO with qualified patent counsel and primary USPTO records.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.